15 months, 100% non-dilutive. Partners: J&J Innovation, Novartis Venture Fund, Pfizer, Roche, AbbVie, Takeda.
Profile being verified · Active right now
What they look for
THE Swiss biotech and pharma programme par excellence. 100% non-dilutive. Big pharma partners (J&J, Novartis, Pfizer, Roche, AbbVie, Takeda) give you direct access to pharma business development teams that could license or acquire you.
What puts them off
Non-biotech startup, no preclinical data, technology without a defined therapeutic application.
How to approach them
Application on baselaunch.ch. Very selective: 5–8 startups per cohort out of hundreds of applications.
Decision process
15 intensive months. Mentoring by scientific and pharma experts. No direct investment, but links with Novartis Venture Fund and others.
Recent investments
Alumni: Numab, Sophia Genetics (former alumni), Crispr Therapeutics. The best Swiss biotechs have passed through.
Rounds tracked by FundSwiss
- Umlaut.bioPre-seed · EUR 3 M